“Phase-19 studies in which the adenoviral vector-based Kovid-19 vaccine developed by Ankara University Cancer Research Institute and supported within the scope of TUBITAK Kovid-1 Platform will be tested on humans have started.
A press conference was held at Ankara City Hospital Clinical Research Center for the adenoviral vector-based Kovid-1 vaccine approved by the Ministry of Health for Phase-19 clinical trial. Ankara University Cancer Research Institute Director, who developed the vaccine, Prof. Dr. Hakan Akbulut pointed out that the vaccine has entered the clinical phase as a result of the studies they started in March 19 within the scope of the TÜBİTAK Kovid-2020 Platform.
Akbulut continued his words as follows: “Our vaccine is an adenoviral vector-based vaccine. How is it different from existing vaccines? Currently, there are mRNA and inactivated vaccines that are widely used in our country and in the world. There are also similar adenoviral vector vaccines. Our vaccine is a bit more innovative in design. Hi-tech adenoviral vector vaccine. It is important for us that such a vaccine can be made in our country and brought to this stage.” Akbulut: "Oral and nasal vaccines can end the pandemic," he said.
TUBITAK President Prof. Dr. Hasan Mandal, in his statement here, reminded that TURKOVAC has now received an emergency use approval, the VLP-based vaccine has also completed Phase-2 and its application for the Phase-2B phase is currently being evaluated. Mandal said, “We had 19 vaccine candidates on the TÜBİTAK Kovid-7 Platform, 3 of which were our vaccines that came to the clinical stage. The Phase-1 study of our adenoviral vector-based vaccine, which is the third of these, will be started.”
Coronavirus Scientific Committee Member Assoc. Dr. Afşin Emre Lostmaz emphasized how important the domestic vaccine production is in the Kovid-19 process, and said that they hope the vaccine will be used in the medium term.
Ankara University Vice Rector Prof. Dr. Hasan Serdar Öztürk, on the other hand, said, “It is a vaccine that we are very hopeful for, that has new technology and that we expect it to be effective against new variants that may emerge. I wish the best for our country," he said. At the press conference, Ankara City Hospital General Hospital Chief Physician Assoc. Dr. İhsan Ateş, Medical Microbiology Clinic Kovid-19 Laboratory Supervisor Assoc. Dr. Bedia Dinç, principal investigator of the vaccine study, Dr. Hürriyet Ekmel Olcay also took part.
Developed by Ankara University Cancer Research Institute and
Adenoviral Vector-Based COVID-19 Vaccine Supported Within the Scope of TÜBİTAK COVID-19 Platform was Introduced pic.twitter.com/XfoC3ykCPl— Ankara University (@AnkaraUni) January 28, 2022
Be the first to comment